Mecamylamine: New therapeutic uses and toxicity/risk profile

Clinical Therapeutics

Volumn 23, Issue 4, 2001, Pages 532-565

  Young, John M ^a   Douglas Shytle, R ^b   Sanberg, Paul R ^b   George, Tony P ^c  

^a JM Young Consulting Inc   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Mecamylamine; Neuropsychiatric; Nicotinic acetylcholine receptor antagonist; Review

Indexed keywords

MECAMYLAMINE; N METHYL DEXTRO ASPARTIC ACID; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT;

ACCOMMODATION PARALYSIS; AGGRESSION; ALCOHOLISM; ANALGESIC ACTIVITY; AUTONOMIC DYSREFLEXIA; BLOOD BRAIN BARRIER; CLINICAL TRIAL; COGNITION; CONSTIPATION; CONVULSION; DRUG DEPENDENCE; DRUG MECHANISM; DRUG TOLERABILITY; DRY SKIN; GANGLION BLOCK; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERTENSION; LD 50; NEUROPSYCHIATRY; NONHUMAN; REVIEW; URINE RETENTION; XEROSTOMIA;

EID: 0035019499     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80059-X     Document Type: Article

References (134)

1. Pharmacology of mecamylamine
2. Nicotinic acetylcholine receptors in health and disease
3. Human neuronal nicotinic receptors
4. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics
5. The acetylcholine receptor of the neuromuscular junction recognizes mecamylamine as a noncompetitive antagonist
6. The molecular biology of neuronal nicotinic acetylcholine receptors
7. Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors
8. Agonist and antagonist effects of nicotine on chick neuronal nicotinic receptors are defined by alpha and beta subunits
9. Antagonist activities of mecamylamine and nicotine show reciprocal dependence on beta subunit sequence in the second transmembrane domain
10. Are nicotinic receptors activated or inhibited following chronic nicotine treatment?
11. Regulation by nicotine of its own receptors
12. Contribution to the pharmacodynamic study of mecamylamine
13. Ganglionic blocking properties of 3-methylaminoisocamphane hydrochloride (mecamylamine): A secondary amine
14. The pharmacological actions of pempidine and its ethyl homologue
15. Actions of mecamylamine, dimecamine, pempidine and their two quaternary metho-salts at the neuromuscular junction
16. The influence of mecamylamine on contractions induced by different agonists and on the role of calcium ions in the isolated rabbit aorta
17. The effects of ganglion blocking agents on the isolated, innervated bladder of the guinea-pig
18. Hypotensive and ganglion blocking action of methyl substituted 3-amino-norcamphanes
19. The effect of reserpine and mecamylamine on experimental atheromatosis in the normotensive and hypertensive rat
20. Differential effect of hypotensive drugs on renal and steroid hypertensive rats
21. The evaluation of cardiovascular drugs in the anaesthetized, unrestrained rat
22. Depression of the vasomotor centre by mecamylamine, independent of its ganglion-blocking activity
23. Effects of mecamylamine on responses of carotid body chemoreceptors in vivo to physiological and pharmacological stimuli
24. Laboratory and clinical observations on mecamylamine as a hypotensive agent
25. The effect of mecamylamine on coronary flow, cardiac work, and cardiac efficiency in normotensive dogs
26. Investigation of the mechanism of the hemodynamic effects of ganglionic blockade produced by mecamylamine
27. Cardiovascular activity of mecamylamine, pempidine, and several pempidine analogs
28. Development of hypertension during chronic mecamylamine administration in dogs
29. Increased sympathetic vasoconstrictor tone in dogs treated chronically with mecamylamine
30. Potentiation of vasoactive drugs by ganglionic blocking agents
31. Further study of the sustained hypertension produced by chronic administration of mecamylamine
32. Some consequences of long-term mecamylamine administration to experimental animals
33. Mecamylamine - A ganglionic blocking agent
34. Effects of autonomic blockade on pulmonary and systemic circulation before and after birth
35. The mechanism of gastric hyperacidity produced by pylorus ligation in the rat
36. Role of gastric acid in aspirin-induced gastric irritation in the rat
37. Effects of enteric microbial overgrowth on small intestinal ultrastructure in the rat
38. The effects of small intestinal colonization by fecal and colonic bacteria on intestinal function in rats
39. Nicotinic receptor mediates spontaneous GABA release in the rat dorsal motor nucleus of the vagus
40. Nicotinic acetylcholine involvement in cognitive function in animals
41. Dose-specific improvements in memory-related task performance by rats and aged monkeys administered the nicotinic-cholinergic antagonist mecamylamine
42. Comparison of learning impairment and activity depression produced by two classes of cholinergic blocking agents
43. Effects of systemic and intracerebroventricular administration of mecamylamine, a nicotinic cholinergic antagonist, on spatial memory in rats
44. Memory modulation with peripherally acting cholinergic drugs
45. Differential effects of scopolamine and mecamylamine on working and reference memory in the rat
46. Effects of U-50,488H on scopolamine-, mecamylamine- and dizocilpine-induced learning and memory impairment in rats
47. Acute nicotine interactions with nicotinic and muscarinic antagonists: Working and reference memory effects in the 16-arm radial maze
48. Correlation of the amnesic effects of nicotinic antagonists with inhibition of regional brain acetylcholine synthesis in rats
49. Nicotine-like behavioral effect after small dose of mecamylamine in Roman high-avoidance rats
50. Effects of nicotine, mecamylamine, and hexamethonium on shock-induced fighting, pain reactivity, and locomotor behaviour in rats
51. The importance of central nicotinic receptors in footshock-induced aggression in mice
52. Basic and clinical psychopharmacology of nicotine
53. Antagonism of nicotine-induced convulsions by ganglionic blocking agents
54. Effects of ganglion blocking agents on nicotine extensor convulsions and lethality in mice
55. Accumbal dopamine overflow after ethanol: Localization of the antagonizing effect of mecamylamine
56. Voluntary ethanol intake in the rat and the associated accumbal dopamine overflow are blocked by ventral tegmental mecamylamine
57. Excitatory amino acids and drugs of abuse: A role for N-methyl-D-aspartate receptors in drug tolerance, sensitization and physical dependence
58. In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists
59. [3H]MK801 binding to the N-methyl-D-aspartate receptor reveals drug interactions with the zinc and magnesium binding sites
60. Effects of nicotinic agonists and antagonists on N-methyl-D-aspartate-induced 3H-norepinephrine release and 3H-(1-[1-(2-thienyl) cyclohexyl]-piperidine) binding in rat hippocampus
61. Both nicotine and mecamylamine block dizocilpine-induced explosive jumping behavior in mice: Psychiatric implications
62. A study of the N-methyl-D-aspartate antagonistic properties of anticholinergic drugs
63. Mecamylamine is a selective non-competitive antagonist of N-methyl-D-aspartate- and aspartate-induced currents in horizontal cells dissociated from the catfish retina
64. Ketamine catalepsy and anesthesia in dogs pretreated with antiserotonergic or antidopaminergic neuroleptics or with anticholinergic agents
65. The influence of adrenergic, dopaminergic, cholinergic and serotoninergic drugs on plasma prolactin levels in ovariectomized, estrogen-treated rats
66. Effect of ganglionic blocking agents on glucose metabolism in the fasting rat
67. Effect of ganglionic blocking agents chlorisondamine and mecamylamine on glucose metabolism and serum insulin in the rat
68. Effects of cholinergic and dopaminergic agents on pain and morphine analgesia measured by three pain tests
69. Potentiation of morphine analgesia by mecamylamine
70. Antagonism of antiinflammatory drugs in bradykinin-induced increase of capillary permeability
71. Pharmacological studies on active bronchial anaphylaxis in the rat
72. Pharmacological properties of pempidine (1:2:2:6:6-pentamethylpiperidine), a new ganglion-blocking compound
73. Nicotine-mecamylamine interactions
74. Neuromuscular disorders in mecamylamine therapy
75. Use of mecamylamine in the management of hypertension
76. Mecamylamine in control of hyperreflexia
77. Autonomic dysreflexia. A survey of current treatment
78. Reduction of bladder contractility after alpha-adrenergic blockade and after ganglionic blockade
79. Nicotinic receptors in the development and modulation of CNS synapses
80. Pharmacology of neuronal nicotinic acetylcholine receptor subtypes
81. Presynaptic nicotinic ACh receptors
82. What is the nature of mecamylamine's antagonism of the central effects of nicotine?
83. Blockade of nicotine selfadministration with nicotinic antagonists in rats
84. Maintenance of schedule-controlled behavior by intravenous injections of nicotine in squirrel monkeys
85. Influencing cigarette smoking with nicotine antagonists
86. Effects of mecamylamine on spontaneous EEG and performance in smokers and nonsmokers
87. Mecamylamine does not precipitate withdrawal in cigarette smokers
88. Clinical evaluation of mecamylamine for withdrawal from nicotine dependence
89. Withdrawal from nicotine dependence using mecamylamine: Comparison of three-week and sixweek dosage schedules
90. Mecamylamine increases nicotine preference and attenuates nicotine discrimination
91. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone
92. Nicotine-mecamylamine for smoking cessation: The role of pre-cessation therapy
93. The neurobiology of drug addiction
94. Neuropharmacology of cocaine and ethanol dependence
95. Nicotine and morphine differentially activate brain dopamine in prefrontocortical and subcortical terminal fields: Effects of acute and repeated injections
96. Effects of repeated nicotine pre-treatment on mesoprefrontal dopaminergic and behavioral responses to acute footshock stress
97. Substance abusers want to stop smoking!
98. Nicotine and caffeine use in cocaine-dependent individuals
99. Relationship of cessation of cocaine use to cigarette smoking in cocaine-dependent outpatients
100. An acute dose of nicotine enhances cue-induced cocaine craving
101. A nicotine antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects
102. The nicotine antagonist mecamylamine reduces cocaine self-administration in rats
103. Overview: Biological processes relevant to drugs of dependence
104. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome
105. Neurobiology of tobacco smoking and other addictive disorders
106. Drugs of abuse and the brain
107. Nicotine addiction
108. Exposure to nicotine enhances acquisition of ethanol drinking by laboratory rats in a limited access paradigm
109. Developmental psychopathology and neurobiology of Tourette's syndrome
110. Tourette syndrome, associated conditions and the complexities of treatment
111. Behavioral and emotional aspects of Tourette syndrome
112. Tourette's syndrome and psychopathology in a child psychiatry setting
113. Parent perceptions of symptom severity in Tourette's syndrome
114. Tourette syndrome: Prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding
115. Tourette's syndrome: A disorder of cingulate and orbitofrontal function?
116. High presynaptic dopaminergic activity in children with Tourette's disorder
117. Cholinergic mechanisms in Gilles de la Tourette's syndrome
118. Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome
119. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder
120. Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome
121. Longlasting improvement of Tourette's syndrome with transdermal nicotine
122. Case study: Long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome
123. Treatment of Tourette's syndrome with mecamylamine
124. Mecamylamine in Tourette's syndrome: A two-year case study
125. Comorbid bipolar disorder in Tourette syndrome responds to nicotinic receptor antagonist, mecamylamine (Inversine®)
126. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function
127. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine
128. Acute nicotinic blockage produces cognitive impairment in normal humans
129. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior
130. Muscarinic and nicotinic contributions to cognitive function and cortical blood flow
131. Combined nicotinic and muscarinic blockade in elderly normal volunteers: Cognitive, behavioral, and physiologic responses
132. The effect of small doses of mecamylamine on shuttlebox behavior in the guinea-pig